Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 37, 2014, Pages 13373-13378

  Rankin, Erinn B ^a   Fuh, Katherine C ^a   Castellini, Laura ^a   Viswanathan, Kartik ^a   Finger, Elizabeth C ^a   Diep, Anh N ^a   LaGory, Edward L ^a   Kariolis, Mihalis S ^a   Chan, Andy ^a   Lindgren, David ^b   Axelson, Håkan ^b   Miao, Yu R ^a   Krieg, Adam J ^c   Giaccia, Amato J ^a  

^a STANFORD UNIVERSITY   (United States)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Hepatocellular carcinoma; Kidney cancer; Targeted therapy; VHL

Indexed keywords

AXL RECEPTOR TYROSINE KINASE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; GROWTH ARREST-SPECIFIC PROTEIN 6; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ONCOPROTEIN; PROTEIN TYROSINE KINASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SIGNAL PEPTIDE; VON HIPPEL LINDAU PROTEIN;

BIOLOGICAL MODEL; CELL HYPOXIA; ENZYME ACTIVATION; ENZYMOLOGY; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; PATHOLOGY; PHENOTYPE; SECONDARY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR INVASION;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL HYPOXIA; CELL LINE, TUMOR; ENZYME ACTIVATION; HEPATOCYTE GROWTH FACTOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; PHENOTYPE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TREATMENT OUTCOME; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84907192193     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1404848111     Document Type: Article

References (45)

1. Escudier B, Szczylik C, Porta C., Gore M. (2012) Treatment selection in metastatic renal cell carcinoma: Expert consensus. Nat Rev Clin Oncol 9(6):327-337.
2. Latif F, et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260(5112):1317-1320.
3. Iliopoulos O, Kibel A, Gray S., Kaelin WG, Jr (1995) Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1(8):822-826.
4. Kibel A, Iliopoulos O, DeCaprio J.A., Kaelin WG, Jr (1995) Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269(5229):1444-1446.
5. Duan DR, et al. (1995) Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269(5229):1402-1406.
6. Pause A, et al. (1997) The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 94(6):2156-2161.
7. Kamura T, et al. (1999) Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284(5414):657-661.
8. Jaakkola P, et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292(5516): 468-472.
9. Ivan M, et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hy-droxylation: Implications for O2 sensing. Science 292(5516):464-468.
10. Staller P, et al. (2003) Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425(6955):307-311.
11. Vanharanta S, et al. (2013) Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med 19(1):50-56.
12. Linger RM, Keating AK, Earp H.S., Graham D.K. (2010) Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets 14(10):1073-1090.
13. Zhang Z, et al. (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44(8):852-860.
14. Ruan GX, Kazlauskas A. (2012) Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J 31(7):1692-1703.
15. Krieg AJ, et al. (2010) Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol Cell Biol 30(1):344-353.
16. Maxwell PH, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399(6733):271-275.
17. Wang GL, Semenza G.L. (1995) Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270(3):1230-1237.
18. Jiang BH, Rue E, Wang G.L., Roe R., Semenza G.L. (1996) Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271(30): 17771-17778.
19. Jiang Y, et al. (2003) Gene expression profiling in a renal cell carcinoma cell line: Dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res 1(6):453-462.
20. Dong ZZ, et al. (2013) Hypoxia-inducible factor-1alpha: Molecular-targeted therapy for hepatocellular carcinoma. Mini Rev Med Chem 13(9):1295-1304.
21. Wang GL, Semenza G.L. (1993) Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 268(29):21513-21518.
22. Keith B, Johnson RS, Simon M.C. (2012) HIF1α and HIF2α: Sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12(1):9-22.
23. Semenza GL (2012) Hypoxia-inducible factors in physiology and medicine. Cell 148(3): 399-408.
24. Mudduluru G, Allgayer H. (2008) The human receptor tyrosine kinase Axl gene-Promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation. Biosci Rep 28(3):161-176.
25. Wei K, et al. (2013) A liver Hif-2α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition. Nat Med 19(10):1331-1337.
26. Linger RM, Keating AK, Earp H.S., Graham D.K. (2008) TAM receptor tyrosine kinases: Biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 100:35-83.
27. Saiki I, et al. (1991) Characterization of the invasive and metastatic phenotype in human renal cell carcinoma. Clin Exp Metastasis 9(6):551-566.
28. Sheridan C (2013) First Axl inhibitor enters clinical trials. Nat Biotechnol 31(9):775-776.
29. Rankin EB, et al. (2010) AXL is an essential factor and therapeutic target for meta-static ovarian cancer. Cancer Res 70(19):7570-7579.
30. Suwaki N, et al. (2011) A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Transl Med 3(85):85ra47.
31. Braunger J, et al. (1997) Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site. Oncogene 14(22):2619-2631.
32. Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4(6):470-480.
33. Dulak AM, Gubish CT, Stabile L.P., Henry C., Siegfried J.M. (2011) HGF-independent potentiation of EGFR action by c-Met. Oncogene 30(33):3625-3635.
34. Gao J, et al. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269): pl1.
35. Cerami E, et al. (2012) The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401-404.
36. Koochekpour S, et al. (1999) The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 19(9):5902-5912.
37. Psyrri A, Arkadopoulos N, Vassilakopoulou M., Smyrniotis V, Dimitriadis G. (2012) Pathways and targets in hepatocellular carcinoma. Expert Rev Anticancer Ther 12(10):1347-1357.
38. Longati P, Bardelli A, Ponzetto C., Naldini L, Comoglio P.M. (1994) Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene 9(1):49-57.
39. Gustafsson A, Boström AK, Ljungberg B., Axelson H, Dahlbäck B (2009) Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma. PLoS ONE 4(10):e7575.
40. Hanna SC, et al. (2013) HIF1α and HIF2α independently activate SRC to promote melanoma metastases. J Clin Invest 123(5):2078-2093.
41. Loges S, et al. (2010) Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood 115(11):2264-2273.
42. Harshman LC, Choueiri T.K. (2013) Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J 19(4):316-323.
43. Nakaigawa N, et al. (2006) Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. Cancer Res 66(7):3699-3705.
44. Gustafsson A, et al. (2009) Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res 15(14):4742-4749.
45. Ben-Batalla I, et al. (2013) Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood 122(14):2443-2452.